Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombin III].

C Boyer-Neumann, M Wolf, M J Larrieu

    Annales De Biologie Clinique
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Antithrombin III (AT III) is a key plasma inhibitor regulating blood coagulation by inactivating serine proteases. Its deficiency significantly increases the risk of thromboembolic disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

    Haemophilia : the official journal of the World Federation of Hemophilia·2015
    Same author

    Epidural analgesia for parturients with type 1 von Willebrand disease.

    International journal of obstetric anesthesia·2007
    Same author

    Screening for bleeding disorders in women with menorrhagia using a platelet function analyzer.

    Journal of thrombosis and haemostasis : JTH·2006
    Same author

    [Glanzmann's thrombasthenia and pregnancy: a case and review of the literature].

    Annales francaises d'anesthesie et de reanimation·2003
    Same author

    Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.

    Journal of thrombosis and haemostasis : JTH·2003
    Same author

    Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome.

    The hematology journal : the official journal of the European Haematology Association·2002
    Same journal

    [The role of the heart-on-a-chip to drug evaluation].

    Annales de biologie clinique·2026
    Same journal

    A morphology-driven proof-of-concept study linking interphase nuclear abnormalities to dicentric-mediated genomic instability.

    Annales de biologie clinique·2026
    Same journal

    Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

    Annales de biologie clinique·2026
    Same journal

    Small-cell secondary plasma cell leukemia mimicking low-grade B-cell lymphoma.

    Annales de biologie clinique·2026
    Same journal

    [Multiple myeloma and analytical discrepancy in serum free light chain assay: a case report].

    Annales de biologie clinique·2026
    Same journal

    [Summary of the 34th National Conference of the National College of Hospital Biochemistry].

    Annales de biologie clinique·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Hematology
    • Molecular Biology

    Context:

    • In vivo regulation of blood coagulation is crucial for hemostasis.
    • Plasma inhibitors, particularly antithrombin III (AT III), play a vital role in controlling coagulation.
    • AT III is a glycoprotein that neutralizes key serine proteases in the coagulation cascade.

    Purpose:

    • To elucidate the role of antithrombin III (AT III) in the in vivo regulation of coagulation.
    • To understand the mechanism of AT III's inhibitory action on serine proteases.
    • To highlight the significance of AT III in preventing thromboembolic events.

    Summary:

    • Antithrombin III (AT III) is a critical plasma inhibitor that inactivates serine proteases during coagulation.
    • The inhibitory activity of AT III is significantly potentiated by heparin and similar heparin-like substances.

    Related Experiment Videos

  • Formation of an equimolecular complex between AT III and proteases leads to their inactivation.
  • Congenital AT III deficiency is strongly associated with a high incidence of thromboembolic disease.

    • Impact:

    • Demonstrates the physiological importance of AT III in preventing thrombosis.
    • Highlights the potential therapeutic role of heparin-like substances in modulating coagulation.
    • Provides insights into the molecular mechanisms underlying coagulation regulation and deficiency-related diseases.